Looking beyond traditional oncogenic pathways to break cancer resistance
Drug Target Review
SEPTEMBER 25, 2024
BRAF and downstream mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors are combined to treat BRAF-mutated melanoma, for example. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.
Let's personalize your content